Elihu H. Estey mainly investigates Internal medicine, Leukemia, Myeloid leukemia, Immunology and Surgery. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology. Leukemia is often connected to Cancer research in his work.
His Myeloid leukemia research is multidisciplinary, incorporating elements of Cancer, Performance status, Fms-Like Tyrosine Kinase 3 and Bone marrow. His work on Chronic myelomonocytic leukemia as part of general Immunology research is frequently linked to In patient, bridging the gap between disciplines. His study looks at the intersection of Surgery and topics like Chlorodeoxyadenosine with Waldenstrom macroglobulinemia.
His primary areas of study are Internal medicine, Myeloid leukemia, Oncology, Leukemia and Gastroenterology. He combines subjects such as Surgery and Immunology with his study of Internal medicine. His Myeloid leukemia research is multidisciplinary, incorporating perspectives in Cancer, Disease, Bone marrow and Cytogenetics.
His research in Oncology tackles topics such as Clinical trial which are related to areas like Intensive care medicine. Elihu H. Estey interconnects Myeloid, Pharmacology and Survival rate in the investigation of issues within Leukemia. His Gastroenterology research incorporates elements of Myelodysplastic syndromes and Toxicity, Phases of clinical research.
Elihu H. Estey focuses on Internal medicine, Myeloid leukemia, Oncology, Myeloid and Leukemia. His study connects Gastroenterology and Internal medicine. His Myeloid leukemia research integrates issues from Mitoxantrone, Newly diagnosed and Hematopoietic stem cell transplantation, Disease.
The Oncology study combines topics in areas such as Clinical trial, Complete remission, Decitabine, Hazard ratio and Myeloid Neoplasm. He has researched Myeloid in several fields, including Young adult, Cancer and MEDLINE. His studies deal with areas such as Logistic regression and Drug resistance as well as Leukemia.
His main research concerns Myeloid leukemia, Internal medicine, Oncology, Leukemia and Myeloid. His Myeloid leukemia study combines topics from a wide range of disciplines, such as Clinical trial, Disease, Transplantation and Intensive care medicine. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Cytogenetics.
Elihu H. Estey works mostly in the field of Oncology, limiting it down to concerns involving Hazard ratio and, occasionally, Proportional hazards model. His research investigates the link between Leukemia and topics such as Surgery that cross with problems in White blood cell. His Myeloid research includes elements of Cancer, Performance status, Mitoxantrone, Survival rate and Drug resistance.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori.
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson;John M. Bennett;Kenneth J. Kopecky;Thomas Büchner.
Journal of Clinical Oncology (2003)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum.
Acute myeloid leukaemia
Elihu Estey;Hartmut Döhner.
The Lancet (2006)
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien.
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
Eric L. Sievers;Richard A. Larson;Edward A. Stadtmauer;Elihu Estey.
Journal of Clinical Oncology (2001)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Miguel A. Sanz;David Grimwade;Martin S. Tallman;Bob Lowenberg.
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Alvaro Aguayo;Hagop M Kantarjian;Taghi Manshouri;Cristi Gidel.
β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome
Zekaver Odabasi;Gloria Mattiuzzi;Elihu Estey;Hagop Kantarjian.
Clinical Infectious Diseases (2004)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials
Robert Kerrin Hills;Sylvie Castaigne;Frederick R. Appelbaum;Jacques Delaunay.
Lancet Oncology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: